Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience

Bibliographic Details
Published in:	Journal of Dermatological Treatment
Main Authors:	Luigi Gargiulo, Francesco Piscazzi, Luciano Ibba, Mario Valenti, Paola Facheris, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Online Access:	http://dx.doi.org/10.1080/09546634.2023.2192840

Similar Items

Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients
by: Francesco Piscazzi, et al.
Published: (2023-12-01)

Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study
by: Luigi Gargiulo, et al.
Published: (2023-04-01)

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study
by: Luigi Gargiulo, et al.
Published: (2024-12-01)

Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience
by: Luigi Gargiulo, et al.
Published: (2023-12-01)

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study
by: Luciano Ibba, et al.
Published: (2024-12-01)

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series
by: Luigi Gargiulo, et al.
Published: (2023-12-01)

Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results
by: Servando E. Marron, et al.
Published: (2021-06-01)

Dupilumab in children and adolescents with atopic dermatitis, a 52-week real-life experience: first report in Colombia
by: Daniela Meléndrez Vásquez, et al.
Published: (2024-10-01)

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks
by: Luciano Ibba, et al.
Published: (2023-06-01)

Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
by: Ibba L, et al.
Published: (2024-03-01)

Predictors for the Efficacy of 4-Week Dupilumab Treatment in Atopic Dermatitis Patients
by: Yu L, et al.
Published: (2025-03-01)

Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis
by: Shinji Mitsuyama, et al.
Published: (2023-04-01)

A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years
by: Cataldo Patruno, et al.
Published: (2023-12-01)

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study
by: Tiago Torres, et al.
Published: (2025-06-01)

Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023-07-01)

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience
by: Gioele Ghezzi, et al.
Published: (2024-11-01)

Conjunctivitis in patients with atopic dermatitis treated with dupilumab
by: Sandra Ferreira, et al.
Published: (2020-05-01)

Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis
by: Marco Ferrari, et al.
Published: (2023-01-01)

The application of the biological treatment in atopic dermatitis: focus on dupilumab
by: Yu. S. Smolkin, et al.
Published: (2023-03-01)

Laboratory Changes During Dupilumab Treatment for Atopic Dermatitis
by: D. Flor, et al.
Published: (2025-05-01)

Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis
by: Mohamed A. Kamal, et al.
Published: (2024-11-01)

Dupilumab in atopic dermatitis patients with chronic hepatitis B
by: Masako Matsutani, et al.
Published: (2022-04-01)

Dupilumab normalizes correlates of lysosomal function in atopic dermatitis
by: Christina Bürgler, et al.
Published: (2024-06-01)

Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient
by: Shiyu Zhang, et al.
Published: (2023-12-01)

New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review
by: Matteo Bianco, et al.
Published: (2025-03-01)

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
by: Luigi Gargiulo, et al.
Published: (2024-03-01)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024-04-01)

High Prevalence of Lash Collarettes in Patients with Atopic Dermatitis Treated with Dupilumab
by: Ilaria Trave, et al.
Published: (2025-08-01)

The Effect of Dupilumab on Growth Parameters in Pediatric Atopic Dermatitis Patients
by: Vincenzo Piccolo, et al.
Published: (2025-07-01)

Comparative Analysis of the Efficacy of Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis
by: Song D, et al.
Published: (2025-04-01)

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01)

Racial and ethnic disparities in dupilumab for pediatric atopic dermatitis in Florida
by: Urdur Jonsdottir, MD, et al.
Published: (2024-11-01)

A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children
by: Wang M, et al.
Published: (2024-03-01)

Drug survival rate of dupilumab in Japanese patients with atopic dermatitis
by: Susumu Ichiyama, et al.
Published: (2021-10-01)

Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
by: I. S. Krysanov, et al.
Published: (2020-09-01)

Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis
by: Emilie Fowler, et al.
Published: (2019-06-01)

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
by: Lotte S. Spekhorst, et al.
Published: (2023-01-01)

Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
by: Mara Giavina-Bianchi, et al.
Published: (2021-05-01)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
by: Marco Dubini, et al.
Published: (2023-09-01)

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers
by: Diego Orsini, et al.
Published: (2023-12-01)